ARROWHEAD PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $1.45 million for the 3-month period ending 2016-12-31, per its 10-Q filed 2017-02-06.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2017-02-06
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-12-31 was $1.45M.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-09-30 was -$523.15K, a 225.78% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-06-30 was -$110.86K.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-03-31 was $363.29K, a 89.30% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was -$293.07K, a 110.92% decline from fiscal 2015.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2015 was $2.68M.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2014 was -$5.82M, a 214.91% decline from fiscal 2013.
- ARROWHEAD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2013 was $5.07M, a 1702.81% increase from fiscal 2012.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | $1.45M 10-Q · filed 2017-02-06 | $931.68K derived: sum of 2 quarters · filed 2017-02-06 | $820.82K derived: sum of 3 quarters · filed 2017-02-06 | $1.18M derived: sum of 4 quarters · filed 2017-02-06 | |||
| 2016-09-30 | -$523.15K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | -$634.01K derived: sum of 2 quarters · filed 2016-12-14 | -$270.73K derived: sum of 3 quarters · filed 2016-12-14 | -$293.07K 10-K · filed 2016-12-14 | |||
| 2016-06-30 | -$110.86K 10-Q · filed 2016-08-09 | $252.43K derived: sum of 2 quarters · filed 2016-08-09 | $230.08K 10-Q · filed 2016-08-09 | $646.77K derived: sum of 4 quarters · filed 2017-02-06 | |||
| 2016-03-31 | $363.29K 10-Q · filed 2016-05-10 | $341.71K 10-Q · filed 2016-05-10 | $757.63K derived: sum of 3 quarters · filed 2017-02-06 | $654.86K derived: sum of 4 quarters · filed 2017-02-06 | |||
| 2015-12-31 | -$21.57K 10-Q · filed 2017-02-06 | $394.34K derived: sum of 2 quarters · filed 2017-02-06 | $291.58K derived: sum of 3 quarters · filed 2017-02-06 | $483.49K derived: sum of 4 quarters · filed 2017-02-06 | |||
| 2015-09-30 | $415.91K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $313.15K derived: sum of 2 quarters · filed 2016-12-14 | $505.06K derived: sum of 3 quarters · filed 2016-12-14 | $2.68M 10-K · filed 2016-12-14 | |||
| 2015-06-30 | -$102.76K 10-Q · filed 2016-08-09 | $89.15K derived: sum of 2 quarters · filed 2016-08-09 | $2.27M 10-Q · filed 2016-08-09 | $2.13M derived: sum of 4 quarters · filed 2016-12-14 | |||
| 2015-03-31 | $191.91K 10-Q · filed 2016-05-10 | $2.37M 10-Q · filed 2016-05-10 | $2.23M derived: sum of 3 quarters · filed 2016-12-14 | $2.97M derived: sum of 4 quarters · filed 2016-12-14 | |||
| 2014-12-31 | $2.18M 10-Q · filed 2016-02-09 | $2.04M derived: sum of 2 quarters · filed 2016-12-14 | $2.78M derived: sum of 3 quarters · filed 2016-12-14 | -$134.65K derived: sum of 4 quarters · filed 2016-12-14 | |||
| 2014-09-30 | -$141.26K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $595.82K derived: sum of 2 quarters · filed 2016-12-14 | -$2.31M derived: sum of 3 quarters · filed 2016-12-14 | -$5.82M 10-K · filed 2016-12-14 | |||
| 2014-06-30 | $737.07K 10-Q · filed 2015-08-04 | -$2.17M derived: sum of 2 quarters · filed 2015-08-04 | -$5.68M 10-Q · filed 2015-08-04 | $5.68M 10-Q · filed 2014-08-12 | |||
| 2014-03-31 | -$2.91M 10-Q · filed 2015-05-11 | -$6.42M 10-Q · filed 2015-05-11 | $9.23M 10-Q · filed 2014-05-06 | ||||
| 2013-12-31 | -$3.51M 10-Q · filed 2015-02-09 | $3.52M 10-Q · filed 2014-02-04 | |||||
| 2013-09-30 | $5.07M 10-K · filed 2015-12-14 | ||||||
| 2013-03-31 | -$29.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-09 | $244.80K 10-Q · filed 2013-05-09 | $600.17K derived: sum of 3 quarters · filed 2013-05-09 | ||||
| 2012-12-31 | $274.45K 10-Q · filed 2013-02-13 | $629.82K derived: sum of 2 quarters · filed 2013-02-13 | |||||
| 2012-09-30 | $355.37K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28 | $281.04K 10-K · filed 2012-12-28 | |||||
| 2012-06-30 | -$74.33K 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |